These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8695873)

  • 1. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G; Hartley CA; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Aug; 88(4):1509-14. PubMed ID: 8695873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
    Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
    Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons.
    Andrews RG; Winkler A; Myerson D; Briddell RA; Knitter GH; McNiece IK; Hunt P
    Stem Cells; 1996 Nov; 14(6):661-77. PubMed ID: 8948024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF).
    Catani L; Gugliotta L; Campanini E; Mangianti S; Gibellini D; Baravelli S; Vianelli N; Lemoli RM; Tura S
    Br J Haematol; 1998 Jan; 100(1):207-18. PubMed ID: 9450813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
    Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
    Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin: biology and clinical potentials.
    Miyazaki H; Kato T
    Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM; MacVittie TJ; Roskos L; Stead RB
    Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
    Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
    J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors.
    Liu Yin JA; Adams JA; Brereton ML; Hann A; Harrison BD; Briggs M
    Br J Haematol; 2000 Mar; 108(4):743-6. PubMed ID: 10792278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
    Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
    Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.